Prostate Cancer Foundation — CureCurrent

Published trials53

Recruiting shown15

Roles1

SourceClinicalTrials.gov

Clinical trials

53 shown

COMPASS Study for Metastatic Castration-resistant Prostate CancerNCT07050433 · collaborator · 2025-08-07

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate CancerNCT06826924 · collaborator · 2025-06-03

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerNCT06616597 · collaborator · 2025-02-13

Training for Men Undergoing Androgen Deprivation Therapy.NCT06449664 · collaborator · 2024-05-01

RecoverPC: Relugolix vs GnRH Agonist in Quality of LifeNCT05765500 · collaborator · 2024-02-12

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE TrialNCT05918263 · collaborator · 2024-01-01

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE TrialNCT06040125 · collaborator · 2024-01-01

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerNCT05766371 · collaborator · 2023-12-15

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate CancerNCT06171139 · collaborator · 2023-12-01

Combination Study of Antibiotics With Enzalutamide (PROMIZE)NCT06126731 · collaborator · 2023-11-02

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerNCT06059118 · collaborator · 2023-10-04

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation TherapyNCT05327465 · collaborator · 2022-08-11

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerNCT05113537 · collaborator · 2022-07-08

Mechanisms of Resistance to PSMA Radioligand TherapyNCT05435495 · collaborator · 2021-10-21

Ablative Therapy in the Management of Prostate CancerNCT03492424 · collaborator · 2018-01-02

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate CancerNCT06305598 · collaborator · 2024-12-19

ACTIVE_NOT_RECRUITING

TmPSMA-02 in mCRPCNCT06046040 · collaborator · 2024-01-31

ACTIVE_NOT_RECRUITING

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerNCT05445609 · collaborator · 2023-06-07

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate CancerNCT05471414 · collaborator · 2022-09-22

ACTIVE_NOT_RECRUITING

RElugolix VErsus LeUprolide Cardiac TrialNCT05320406 · collaborator · 2022-06-06

ACTIVE_NOT_RECRUITING

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate CancerNCT04716725 · collaborator · 2021-09-28

Telaglenastat + Talazoparib In Prostate CancerNCT04824937 · collaborator · 2021-07-01

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology ValidationNCT04457232 · collaborator · 2020-09-09

ACTIVE_NOT_RECRUITING

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET StudyNCT04447703 · collaborator · 2020-08-27

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.NCT04116775 · collaborator · 2019-10-30

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerNCT04090528 · collaborator · 2019-10-21

ACTIVE_NOT_RECRUITING

Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation TherapyNCT03761160 · collaborator · 2019-07-16

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT03805594 · collaborator · 2019-05-10

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate CancerNCT03477864 · collaborator · 2018-12-24

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerNCT03532217 · collaborator · 2018-09-14

Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate CancerNCT05078151 · collaborator · 2018-09-01

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate CancerNCT02881242 · collaborator · 2018-01-30

ACTIVE_NOT_RECRUITING

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate CancerNCT03358563 · collaborator · 2018-01-17

Phase I Trial of 225Ac-J591 in Patients With mCRPCNCT03276572 · collaborator · 2017-10-10

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTNCT03007732 · collaborator · 2017-05-17

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair DeficienciesNCT02985021 · collaborator · 2016-11-01

Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate CancerNCT02856100 · collaborator · 2016-08-03

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate CancerNCT02478125 · collaborator · 2016-07-01

Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPCNCT02677376 · collaborator · 2016-06-27

PROMOTE: Identifying Predictive Markers of Response for Genitourinary CancerNCT02735252 · collaborator · 2016-05-25

ACTIVE_NOT_RECRUITING

Non-contrast MR Imaging for Whole Body Cancer Detection and CharacterizationNCT03440554 · collaborator · 2016-03-24

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate CancerNCT02499835 · collaborator · 2015-07-01

Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8NCT02470936 · collaborator · 2015-06-01

Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studYNCT02269982 · collaborator · 2015-05-14

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.NCT02445976 · collaborator · 2015-05-01

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerNCT01990196 · collaborator · 2014-09-23

ACTIVE_NOT_RECRUITING

Radium 223 in Castrate Resistant Prostate Cancer Bone MetastasesNCT02135484 · collaborator · 2014-09-19

Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)NCT02080650 · collaborator · 2014-03-01

Effect of Sulforaphane on Prostate CAncer PrEventionNCT01950143 · collaborator · 2013-08-01

Cabozantinib in Men With Castration-Resistant Prostate CancerNCT01703065 · collaborator · 2013-06-18

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture MethodNCT02025413 · collaborator · 2011-11-01

Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate CaNCT01289067 · collaborator · 2010-12-01

Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate CancerNCT01417182 · collaborator · 2010-09-01

Sponsor roles

collaborator53

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.